Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107016 · ClinicalTrials.gov registry record · Phase 2
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
A Phase 2 study of Breast Neoplasm, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
- 20
- Study locations
NCT00107016 is a Phase 2 study of Breast Neoplasm that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 267 participants, above the 153-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00107016, a Phase 2 study of Breast Neoplasm, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
Conditions Studied
Interventions
- DRUG Letrozole 2.5mg
- DRUG RAD001, Letrozole 2.5mg
Study Locations (20)
Other
- Novartis Investigative Site - Salzburg
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Wilrijk
- Novartis Investigative Site - Natasha
- Novartis Investigative Site - Winnipeg
- Novartis Investigative Site - Besançon
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Montpellier
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Saint-Herblain
California
- Breastlink Medical Group Inc. - Long Beach
- UCSF Breast Care Center - San Francisco
Arkansas
- Highlands Oncology Group - Springdale
Florida
- University of Miami - Miami
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Investigative Clinical Research of Indiana - Indianapolis
Louisiana
- Ochsner Clinic Foundation - New Orleans
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107016
The ClinicalTrials.gov registry entry for NCT00107016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (75% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Letrozole 2.5mg is the first listed.
NCT00107016 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00107016 about?
NCT00107016 is a clinical study titled "Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women". The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
What is the current status of trial NCT00107016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2005-03. Estimated completion is 2007-04.
What conditions does trial NCT00107016 study?
This clinical trial studies the following conditions: Breast Neoplasm.
What interventions are being tested in trial NCT00107016?
The interventions under investigation include: Letrozole 2.5mg (DRUG), RAD001, Letrozole 2.5mg (DRUG).
Who is sponsoring clinical trial NCT00107016?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107016 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RECRUITING · Phase 2
-
Proton Radiation for Stage II/III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
COMPLETED · Phase 2
-
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
COMPLETED · Phase 2
-
Surviving Daily Life
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.